Privosegtor Shows Promise in Optic Neuritis Trial Data
New trial results suggest this drug candidate may improve visual function for patients with optic neuritis.
Updated on Oct. 29, 2026 in Stroke
Live Poll
Do you believe current drug development processes effectively prioritize the most urgent medical needs?
Oculis is presenting new data for its drug candidate Privosegtor, which has shown promise in improving visual function for patients with optic neuritis. This investigational treatment is being highlighted at two upcoming medical conferences as its clinical development progresses.
Why it matters
Optic neuritis is a condition that can lead to vision loss, making the development of neuroprotective treatments a critical area of interest for patients and clinicians. These new findings contribute to the ongoing evaluation of therapies that could eventually preserve retinal structure.
The ACUITY Phase 2 trial evaluated Privosegtor in patients with acute optic neuritis, showing improvements in visual function, retinal preservation, and reduced blood neurofilament levels. These findings are considered preliminary as clinical development continues.
The players
Oculis
A biopharmaceutical company based in Switzerland focusing on the development of eye-care treatments.
Riad Sherif
A presenter and industry expert who provides clinical overviews on ophthalmologic development.
Aaron Tansy
A clinical researcher presenting data from the ACUITY trial.
The details
Privosegtor is a peptoid small-molecule candidate designed to cross the blood-brain and retinal barriers. By targeting these areas, the drug aims to offer neuroprotective benefits, which investigators believe may help mitigate damage to the optic nerve. The drug has already received Breakthrough Therapy designation from the FDA and PRIority Medicines status from the European Medicines Agency.
Timeline
October 30th - November 1st, 2026: The 6th Asia-Pacific Ophthalmic Innovation Society Congress takes place in Seoul.
November 1st, 2026: Riad Sherif presents an overview of Privosegtor.
November 1st - 4th, 2026: The CNS Summit occurs in Everett, Massachusetts.
November 2nd - 3rd, 2026: Aaron Tansy presents the ACUITY trial data.
Q4 2026: Oculis anticipates IND clearance for multiple sclerosis treatment.
Health Landscape
The development of Privosegtor occurs alongside various efforts to improve neuroprotective options for patients with optic nerve inflammation. This work follows the FDA Breakthrough Therapy designation program intended to expedite the review of drugs showing clinical potential.
Patients currently managing optic neuritis should follow these updates as indicators of shifting clinical options. Conversations about new trial findings and emerging treatments remain essential to have with a neurologist or ophthalmologist.
The takeaway
Privosegtor represents a novel approach to neuroprotection for those facing optic nerve-related vision loss. Patients should continue to monitor their vision changes and discuss current and upcoming treatment options with their care team.
What happens next
Oculis anticipates clearance of an IND for the treatment of acute multiple sclerosis relapses in Q4 2026.
Further reading
Learn more about the latest innovations in ocular health in our Stroke section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe current drug development processes effectively prioritize the most urgent medical needs?
